Abaloparatide (Tymlos™) is a synthetic peptide analogue of human parathyroid 
hormone-related protein that was developed by Radius Health as an osteoanabolic 
agent for the treatment of postmenopausal osteoporosis. Abaloparatide acts 
through selective activation of the parathyroid hormone type 1 receptor 
signalling pathway. In April 2017, subcutaneous abaloparatide received its first 
global approval, in the USA, for the treatment of postmenopausal women with 
osteoporosis at high risk for fracture, defined as a history of osteoporotic 
fracture, multiple risk factors for fracture, or patients who have failed or are 
intolerant to other available osteoporosis therapy. A Marketing Authorization 
Application for subcutaneous abaloparatide for the treatment of postmenopausal 
women with osteoporosis was accepted by the European Medicines Agency and is 
currently under review. Radius is also developing a transdermal formulation of 
abaloparatide, with administration via a microneedle patch. This article 
summarizes the milestones in the development of abaloparatide leading to this 
first approval for the treatment of women with postmenopausal osteoporosis.